Compare Star Bulk Carriers Corp (SBLK) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs Summit Therapeutics Inc — how do they compare? Star Bulk Carriers Corp trades at $29.69 (market cap $3.54B), while Summit Therapeutics Inc trades at $17.44 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 3.9× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.17% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Star Bulk Carriers Corp for 24 Days and Summit Therapeutics Inc for 16 Days on average.
| SBLK | SMMT | |
|---|---|---|
Market Cap | $3.54B | $13.71B |
Volume | 1,437,622 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $32.49 | $26.38 |
52-Week Low | $16.79 | $12.43 |
Typical Hold Time | 24 Days | 16 Days |
Enterprise Value | $4.22B | $13.04B |
Dividend Yield | 6.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $29.75, up 0.2% today, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals, with Q2 2026 EPS of $1.21 beating estimates by 27% and a 45% year-over-year revenue surge. A $0.90 dividend for H2 2026 reflects robust free cash flow generation. Analyst consensus is strongly positive, with 14 buys out of 24 ratings, supported by recent insider buying activity.
The outlook for SBLK remains favorable due to consistent earnings beats, attractive valuation multiples, and management's commitment to returning capital. Key risks include shipping rate volatility and broader economic sensitivity. The stock presents a compelling opportunity for value and income investors, though exposure to cyclical industry trends warrants monitoring.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
